# A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients

> **NCT01210768** · PHASE2 · UNKNOWN · sponsor: **TTY Biopharm** · enrollment: 254 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Epirubicin+Cyclophosphamide
- **DRUG:** liposomal-doxorubicin+Cyclophosphamide

## Key facts

- **NCT ID:** NCT01210768
- **Lead sponsor:** TTY Biopharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-06
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 254 (ESTIMATED)
- **Last updated:** 2021-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01210768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01210768, "A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01210768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*